Generic Drug Co. Can Continue Arbitration Against Ranbaxy

Law360 (March 13, 2018, 7:13 PM EDT) -- A Texas appellate court on Monday allowed a generic drug developer to move forward in arbitration with claims it had been fraudulently induced to assign patent rights to Ranbaxy Inc., reversing a trial court’s determination that the arbitration panel had missed a key deadline.

The trial court's finding conflicted with the arbitration panel's own interpretation of the time limit, the Fifth Court of Appeals in Dallas said, adding it’s outside the power of the court to vacate an arbitration finding because of a complaint the panel...
To view the full article, register now.
Law360 Pro Say Podcast
Check out Law360's new podcast, Pro Say, which offers a weekly recap of both the biggest stories and hidden gems from the world of law.